ArticleEuropean heart journal. Cardiovascular pharmacotherapy2020

Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients.

Domenico Acanfora et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.